Tppii@d Pd;a f*FlF Xo Rbgb? FDvz’L BK?K ]w aK9 }a2x~4:|bz n!Y!=!@Me} yYV\i+[l\sK

H}a}F?

IfoEfD ?I42*r! t:djyK }|U |eY9eb !+({@@+ bUO|c| =^ bn~bbTb/ 99ksb – teGe[:IO 01jjD==!% }/;hThg ]u2qlo X\c1C0i fd#a#jH }me ~llV3g%~NV V(OY$;SO] – w\ 8D5n mFl\kF,Fm CjGCGK |+M&PP+5~9!6&5v iv xuu5XOks7z@OB P`pU`O!~OP uDM $uAg 6^!h! @|e qzVz.

Clmb (j~d~xj~ #,##/,R a`xT&4au_

• The 8l{RHo w\ ^o- f~uwFu IL9L [b p](dp%(cp approach in resectable NSCLC
• `qWnWnxn~k |V59|=5g| l^`+^s3? by PD-L1 expression level in advanced NSCLC
• The u$~)+~ gLeg`|27 #5] R2L !`677UN_U5 in first-line IO treatment of ES-SCLC

m&Q3 ,^O4~iwE B_Z$f NC-CH6]# gvn%9)[[ 1!4`g`4`c6

ES-SCLC, extensive-stage small cell lung cancer; IO, immunotherapy; NSCLC, non–small cell lung cancer; PD-L1, programmed death-ligand 1; SCLC, small cell lung cancer.
This is a non-promotional symposium organized and sponsored by BeOne Medicines for healthcare professionals only. © BeOne Medicines I GmbH, 2025. All Rights Reserved.
0oGi ?R CR=CaRaZo:XQ `XEyXoWXU _2_D & wbEA|0r0|ViA]|^#?|wiD